Feature | June 16, 2009

Covidien Warns Clients of Mo-99 Shortages

June 16, 2009 - In response to the molybdenum 99 (Mo-99) supply shortage, Covidien sent out a letter to its customers informing them of the anticipated Covidien generator and unit dose (UD) Tc 99m supply to the overall U.S., Canadian and Latin American markets through August 2009.

The update noted the National Research Universal (NRU) reactor in Chalk River, Canada, will be out of service for at least three months as reported by the Atomic Energy of Canada Ltd.; and the High Flux Reactor (HFR) in Petten, The Netherlands, has a planned shutdown in early July that is expected to last a few days.

Covidien has made arrangements through its diversified supply chain to the remaining online reactors in Belgium and South Africa, and have increased orders for Mo 99 from each reactor to partially offset the shortages caused by the HFR routine maintenance and ongoing NRU reactor shutdown.

Despite these efforts, the company expects there will still be a global shortage of Tc 99m generators during this period.

Covidien stated it should be able to supply its current customers, but not fully meet new demand coming from an influx of facilities seeking alternative suppliers of Mo-99. The company cautioned that at times it may not be able to fully meet even its current clients’ demand.

For more information: www.covidien.com

Related Content

University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers| April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers| April 11, 2017
April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt...
GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers| April 05, 2017
April 5, 2017 — GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered
PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging| March 03, 2017
In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new...
Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers| March 01, 2017 | Anamika Kumari
Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial r
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging| January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
News | Radiopharmaceuticals and Tracers| January 17, 2017
NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s National...
Medrad Intego PET Infusion System, recall
News | Nuclear Imaging| January 12, 2017
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Admini
SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals
News | Radiopharmaceuticals and Tracers| December 28, 2016
December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States Pharmac
NAS report, National Academies of Sciences Engineering and Medicine, Mo-99 production, highly enriched uranium, HEU, SNMMI
News | Radiopharmaceuticals and Tracers| October 28, 2016
The National Academies of Sciences, Engineering, and Medicine (NAS) have released a report on the state of molybdenum-...
Overlay Init